Technician handling samples for NAD research

2026 Meta Analysis: NMN vs NR Shows No Consistent Functional Benefit

Both nicotinamide mononucleotide and nicotinamide riboside raise circulating NAD+ in humans, and no independently replicated clinical trial has proven one produces better health outcomes than the other. Some recent head-to-head reporting has suggested larger blood NAD+ increases with NR, though those figures come from secondary reporting and deserve caution rather than certainty. Readers who decide NMN fits their goals will find a product range covered further down.

TL;DR:

  • Current evidence does not definitively show that NMN produces better health outcomes than nicotinamide riboside, despite some reports of higher blood NAD+ increases with NR.
  • NMN and NR reach NAD+ through different pathways, but tissue-specific transport and first-pass metabolism complicate predicting which supplement is more effective.
  • Human trials show both precursors increase blood NAD+ levels, but functional benefits like improved muscle or cognitive performance are unsupported by conclusive evidence.
  • Short-term safety for both compounds appears tolerable with mostly mild side effects, but long-term data remains limited and people with health conditions should consult a clinician.
  • Choosing between NMN and NR should be based on goals, budget, and formulation preference, as no clear clinical superiority currently exists.
Vivetus
Explore Supplements For Healthy Aging
Vivetus offers scientifically backed dietary supplements designed to support healthy aging, vitality, and quality of life.

Table of Contents

How NMN and NR convert to NAD+: transporters, enzymes and first pass metabolism

NR and NMN reach NAD+ through different doors. NR enters cells mainly via equilibrative nucleoside transporters, then gets phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) into NMN, which is then converted to NAD+ by NMNAT enzymes. NMN, in principle, starts one step closer to the finish line, but its extra phosphate group makes it a larger, more polar molecule, and cell membranes are not naturally built to let it through unmodified.

That gap in the model led researchers to a transporter called Slc12a8, proposed as a dedicated NMN importer in mouse gut tissue. A 2021 review of precursor comparisons covers this evidence and notes that findings are inconsistent across tissues and species, so the existence of a clean, direct NMN transport route in humans is not settled. Many researchers still think NMN is phosphorylated to NR before entering cells, which would mean both molecules ultimately travel a shared final stretch of the same pathway.

First pass metabolism complicates the picture further. After oral dosing, both precursors pass through the gut and liver before reaching the bloodstream, and a portion is cleaved down to nicotinamide along the way. Gut microbiota can also process these compounds before absorption is complete, which helps explain why oral bioavailability and blood NAD+ responses vary between individuals taking what looks like an identical dose.

This is also why the matrix used to measure NAD+ matters. Blood levels are the easiest thing to sample, but they do not necessarily track what happens inside muscle, brain or liver tissue, where the biological effects that matter would actually occur.

  • NR uses nucleoside transporters and NRK enzymes, converting to NMN before becoming NAD+.
  • NMN may use a disputed Slc12a8 route or may first be broken down to NR, per the 2021 precursor review.
  • First pass metabolism in the gut and liver, aided by microbiota, converts part of an oral dose to nicotinamide before it reaches circulation.
  • Blood NAD+ is a convenient marker but is not the same as tissue NAD+, so a rise in blood levels does not confirm a matching rise where it would count biologically.

The practical takeaway is that neither molecule has a mechanistic advantage clear enough, on paper, to predict which one performs better in a living human body. Background on NAD+ biology and why the body needs it is covered in more detail in Vivetus’ explainer on NAD+ supplementation.

Human evidence and pharmacokinetics: what the trials actually show

The clinical record for both precursors is smaller than the marketing around them suggests, and comparing the two directly is harder than it looks.

Randomised human trials of NR, including work by Martens and colleagues, reported measurable increases in blood NAD+ over several weeks of daily dosing, with the size of the rise depending on dose and duration. An early NR pilot study reported a large single dose NAD+ increase, but that trial was industry linked, and its results should be read as a signal rather than a settled figure.

NMN trials tell a similar general story with a thinner evidence base. Human NMN trials indexed on PubMed show increases in blood NAD+ alongside occasional functional signals, such as improved walking speed or sleep scores in small groups, but these studies tend to be short, small and concentrated in a limited number of research centres, mostly in Japan.

A 2025 systematic review and meta-analysis found insufficient evidence that either NMN or NR improves muscle function outcomes in older adults, with pooled effects landing at null for key functional endpoints. That is a meaningful finding: NAD+ levels rise fairly consistently across trials of both compounds, yet the downstream functional benefits people actually care about (strength, gait speed, cognitive performance) have not shown up reliably once the data is pooled.

Several structural problems explain why head-to-head comparisons remain weak rather than definitive:

  • Molar dose asymmetry: NR trials have often used higher molar doses than NMN trials, so a raw milligram comparison misrepresents the actual precursor load delivered.
  • Assay inconsistency: different labs use different NAD+ quantification methods, and results are not always directly comparable across studies.
  • Population heterogeneity: trial participants range from young healthy adults to older adults with metabolic conditions, which changes baseline NAD+ status and response.
  • Short trial durations: most human trials run for weeks rather than months, leaving long term outcomes largely unmeasured.

A 2026 preprint mapping the evidence gap between NMN and NR documents exactly this heterogeneity and argues that equimolar dosing and harmonised NAD+ assays are needed before any fair comparison is possible. Until trials are designed that way, claims that one precursor “wins” on blood NAD+ increase should be treated as provisional. The widely circulated 2026 report suggesting NR produces a larger rise than NMN falls into this category. Its full text sits behind a paywall, and the percentages attached to it are secondary reporting rather than a peer reviewed head to head trial, so they are worth noting, not treating as proof.

Safety and tolerability: what the trials report and what remains unknown

Short term human trials of both NR and NMN generally describe the compounds as well tolerated, with adverse events skewing mild.

  • Gastrointestinal effects, including mild nausea or stomach discomfort, appear occasionally in trial reports for both precursors.
  • Transient effects such as flushing or headache have been noted in isolated cases, typically resolving without intervention.
  • No robust liver-safety signal has emerged from randomised trials to date, though safety review data covering multiple trials still describes the overall evidence base as short term.

The bigger caveat is duration. Most trials run for a matter of weeks, so data on high dose, long term use in humans remains thin for both compounds. People with existing liver or kidney conditions, those who are pregnant or breastfeeding, and anyone on regular medication should speak with a clinician before adding either supplement, since trial populations rarely include these groups in meaningful numbers.

An internal 12 week Dutch trial of NMN tolerability is covered in the publisher perspective section below.

Pro Tip: Start at the lower end of a trial-tested dose range and track how you feel for the first two weeks before considering any increase.

How to choose between NR and NMN: a practical rubric

Neither precursor has a clear evidence-based edge, so the decision often comes down to goals, budget and formulation preference rather than a definitive biological winner.

  1. Define your goal first. If you want the fastest measurable rise in blood NAD+, NR has slightly more human dosing data behind that specific outcome; if you are looking at long term maintenance, the current evidence does not clearly favour either compound.
  2. Consider molar dosing, not just milligrams. Because NMN and NR have different molecular weights, a straight milligram to milligram comparison between products is not a fair equivalence, per the 2026 evidence-gap analysis.
  3. Check third-party testing and label clarity. A trustworthy product states the exact dose per serving and how it was tested, not just a proprietary blend claim.
  4. Confirm storage and stability guidance. Both precursors are sensitive to heat and moisture, so packaging and storage instructions matter for potency over time.
  5. Review refund and subscription terms before committing to a recurring order, since preferences and tolerance can shift after the first few weeks.

Shopping checklist for either compound:

  • Clear labelling of dosage per capsule or scoop, not a vague blend percentage.
  • Independent purity or contaminant testing disclosed by the seller.
  • A defined refund window in case the product does not suit you.
  • Sensible packaging that protects against light, heat and moisture.

Readers weighing NMN specifically can find a fuller breakdown in Vivetus’ guide to buying NMN, including dosing notes tailored for adults over fifty.

Vivetus perspective and internal evidence on NMN use

Vivetus ran a 12 week trial among Dutch adults taking NMN, tracking self-reported tolerability alongside dosing patterns, with findings summarised in a dedicated side-effects overview. Reported effects were generally mild and consistent with the tolerability signals seen in published RCTs, though this internal observation is not a substitute for a peer reviewed trial.

NMN is sold in more than one format because preference varies:

  • Powder suits people who want flexible, adjustable dosing or prefer mixing a supplement into a drink.
  • 250 mg capsules suit those wanting a lower, measured daily starting dose without weighing anything out.
  • 500 mg capsules suit people already familiar with their tolerance who want fewer capsules per dose.

This section reflects editorial and internal observational perspective, not medical advice, and should not replace guidance from a qualified clinician.

Our take: chase the mechanism less, the trial design more

Our take: chase the mechanism less, the trial design more — overview diagram

The most useful lesson from the NMN versus NR debate is not which molecule wins. It is that a rise in blood NAD+ has become a proxy for health benefit without nearly enough trial evidence connecting the two. Conventional advice treats a bigger NAD+ number as inherently better, but the 2025 meta-analysis found that pooled functional outcomes stayed flat despite that rise, which should temper any confident claim from either camp.

Readers chasing the “winning” precursor are asking the wrong question at this stage. The right priority is trial quality: dose consistency, assay standardisation and duration long enough to catch something meaningful. Until that kind of head-to-head study exists, picking between NMN and NR is closer to a formulation and lifestyle choice than a settled clinical decision. Anyone making that choice should weigh tolerability, budget and personal response over marketing claims about percentage increases.

— Jord

Vivetus NMN: powder and capsule options to consider

Choosing NMN over NR does not have to mean guessing at quality. The NMN range is formulated in the Netherlands with transparent dosing and vegan, GMO-free ingredients, so the label matches what is actually in the product.

Vivetus® NMN poeder

  • Vivetus® NMN poeder gives flexible dosing for anyone who wants to adjust intake gradually.
  • Vivetus® NMN, 60 x 250 mg capsules suits a straightforward daily starting dose.
  • Vivetus® NMN, 60 x 500 mg capsules suits those wanting fewer capsules once tolerance is established.

Anyone taking medication or managing a health condition should speak with a clinician before starting NMN. Browse the full Vivetus® NMN collection to compare formats and find the one that fits your routine.

Sources

FAQ

Should I take NR or NMN?

Neither precursor has proven clinical superiority over the other, so the choice depends on your goals, budget and how your body responds. Both raise blood NAD+ in human trials, though the 2025 meta-analysis found no consistent functional benefit for either.

Is it safe to take NR and NMN together?

There is no robust human trial data specifically testing NR and NMN combined, so any combined use should be discussed with a clinician first. Short-term trials of each compound individually generally report mild tolerability, per safety review data.

Is NMN hard on the liver?

Randomised human trials to date have not reported a robust liver-safety signal for NMN, though most trials only run for a matter of weeks. Anyone with existing liver conditions should consult a clinician before starting NMN, since trial populations rarely include this group.

Is NMN the same as nicotinamide riboside?

No, NMN and nicotinamide riboside are different molecules that both raise NAD+ but through different uptake and conversion steps. NR uses nucleoside transporters and NRK enzymes, while NMN’s entry route is still debated, as covered in the 2021 precursor review.

Torna al blog